A Phase 3 interventional study of Subcutaneous Insulin and Inhaled Insulin in Diabetes Mellitus and Chronic Obstructive Pulmonary Disease, sponsored by Pfizer. Terminated at 88 sites in 5 countries. Open to participants aged 30 Years to 77 Years. Per ClinicalTrials.gov, last updated 2010-02-02.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing insulin in Diabetes Mellitus — 1 open to participants now, 2 under way, none of them phase 3. Insulin · Diabetes Mellitus.
Among the 51 studies testing insulin in Diabetes Mellitus, this one is the 21st largest by enrollment of the 49 interventional ones that give a count, is one of 4 that started in 2003, is one of 11 in phase 3, and was the 5th registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →1 of the 51 studies testing insulin in Diabetes Mellitus is open now, in 1 country. Recruiting first, the newest first:
Ohio State University · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.
This study: 30 Years to 77 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 12 · Phase 3 11 · Phase 4 12
First in 1994; this study’s year is marked. 4 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 105 is above the median of 80 across 6,025 interventional studies indexed under Diabetes Mellitus.
Median enrollment 74 across the 49 interventional studies. Of the 44 that completed or were terminated, 18 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 51 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
35 studies in Diabetes Mellitus by Pfizer: 2 open now, 3 under way, 3 of them phase 3. Of 30 finished, 15 (50%) have results posted.
Among the 35 studies in Diabetes Mellitus by Pfizer, this one is the 19th largest by enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2003, is one of 12 in phase 3, and was the 6th registered.
Pfizer’s Diabetes Mellitus studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 51 studies testing insulin in Diabetes Mellitus, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 35 in Diabetes Mellitus:
This tab as a report to print or save as PDF → With an account.
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics with Chronic Obstructive Pulmonary Disease.
Pfizer announced in October 2007 that it would stop marketing Exubera. At that time recruitment for study A2171030 was placed on hold. Nektar, the company from which Pfizer licensed Exubera, announced on April 9, 2008 that it had stopped its search for a new marketing partner. Accordingly, there will be no commercial availability of Exubera. As a result, study A2171030 was terminated on June 17, 2008. Neither safety nor efficacy reasons were the cause of the study termination.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Subcutaneous Insulin
Drug: Inhaled Insulin
Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.
Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.
Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
FEV1 was measured in liters (L) 30 minutes following the administration of ipratropium. Change from baseline: mean of (value of observed FEV1 (L) at treatment duration minus baseline value).
Time frame: Baseline, Weeks 1, 2, 3, 4, 6, 12, 18, 26, 39, 52
Change From Baseline in Post-Bronchodilator Carbon Monoxide Diffusion Capacity (DLco)
DLco measured in milliters/minutes/millimeters of mercury (mL/min/mmHg) 30 minutes following the administration of ipratropium. Change from baseline: mean of (value of observed DLco (mL/min/mmHg) at treatment duration minus baseline value).
Time frame: Baseline, Weeks 1, 2, 3, 4, 6, 12, 18, 26, 39, 52
Full Pulmonary Function Tests (PFTs) (Spirometry, Pre-Ipratropium and Pre-Insulin PFTs)
Full PFTs included spirometry pre- and 30-minutes post-ipratropium and were completed between the hours of 6 AM and 10 AM with subjects in the fasting state. Full PFT data were collected, but not analyzed.
Time frame: Duration of the study
Full PFTs (DLco, Pre-Ipratropium and Pre- Insulin PFTs)
Full PFTs included DLco pre- and 30-minutes post-ipratropium and were completed between the hours of 6 AM and 10 AM with subjects in the fasting state. Full PFT data were collected, but not analyzed.
Time frame: Duration of the study
Other PFTs (Besides FEV1 and DLco)
Other PFTs (besides FEV1 and DLco) were measured 30 minutes following the administration of ipratropium. Other PFTs included forced vital capacity (FVC), peak expiratory flow rate (maximal forced expiratory flow) (PEFR\[FEFmax\]), and forced expiratory flow from 25% to 75% of vital capacity (FEF25%-75%). Other PFT data were collected, but not analyzed.
Time frame: Duration of the study
Bronchodilator Responsiveness as Determined by the Change in FEV1
Responsiveness was the percent change from the FEV1 value before bronchodilator use to the FEV1 value 30 minutes after bronchodilator use, operationally defined as \[(post-bronchodilator FEV1 minus pre-bronchodilator FEV1 divided by pre-bronchodilator FEV1\] multiplied by 100.
Time frame: Weeks 1, 2, 3, 4, 6, 12, 18, 26, 39, 52
Insulin Dose Responsiveness for FEV1
FEV1 dose responsiveness 10 and 60 minutes after insulin. FEV1 dose-responsiveness to insulin (defined as the difference between the FEV1 value following a dose of insulin and FEV1 value before a dose of insulin, operationally defined as the post-dose FEV1 value minus pre-dose FEV1 value).
Time frame: Baseline, Week 9, Week 51
Insulin Dose Responsiveness for DLco
DLco dose responsivness 10 and 60 minutes after insulin. DLco dose-responsiveness to insulin (defined as the difference between the DLco value following a dose of insulin and DLco value before a dose of insulin, operationally defined as the post-dose DLco value minus pre-dose DLco value).
Time frame: Baseline, Week 9, Week 51
Methacholine PC20
Methacholine challenge testing was conducted at selected sites at visits which did not occur at other sites (Weeks -2.9, -0.9, 11, 50 and 52+5). Methacholine challenge was not analyzed as there was only 1 test performed, which was a baseline test, and no methacholine tests performed in subjects using inhaled insulin.
Time frame: Duration of the study
Mean Weekly Number of Puffs of Short-Acting Bronchodilator Used
All subjects used diary cards to record their daily use of short-acting bronchodilators. Subjects recorded the sum of their short-acting bronchodilator use (puffs of albuterol plus ipratropium plus Combivent®, as applicable) daily, immediately upon arising, and again in the evening or before bed. Mean weekly number of puffs of short-acting bronchodilator used data were collected, but not analyzed.
Time frame: Duration of the study
Incidence of Non-Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations
Non-severe COPD exacerbation = additional therapy (systemic corticosteroids, antibiotics, oxygen) needed for worsening respiratory symptoms and/or lung function, not needing hospitalization \> 24 hours. Crude event rate = total events divided by subject-months. Subject-months=elapsed number of months a subject was in the study in each time interval.
Time frame: 0 to 1 week to > 9 months
Incidence of Severe COPD Exacerbations
Severe COPD exacerbation = a COPD-related hospitalization \> 24 hours. Crude event rate = total events divided by subject-months. Subject-months=elapsed number of months a subject was in the study in each time interval.
Time frame: 0 to 1 week to > 9 months
Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) Questionnaires
The BDI and TDI measured or quantitated the severity of breathlessness (shortness of breath) in symptomatic subjects. BDI and TDI data were collected, but not analyzed.
Time frame: Duration of the study
Change From Baseline in Glycosylated Hemoglobin (HbA1c)
Change from baseline: mean of (value of observed HbA1c at treatment duration minus baseline value).
Time frame: Baseline, Weeks 6, 12, 26, 39, and 52
Change From Baseline in Fasting Plasma Glucose
Change from baseline: mean of (value of observed fasting plasma glucose in milligrams/deciliters (mg/dL) at treatment duration minus baseline value).
Time frame: Baseline, Weeks 6, 12, 26, 39, 52
Change From Baseline in Body Weight
Change from baseline: mean of (value of observed body weight in kilograms (kg) at treatment duration minus baseline value).
Time frame: Baseline, Weeks 1, 2, 3, 4, 6, 9, 11, 12, 18, 26, 39, 50, 51, 52
Mean Total Daily Intermediate-/Long-Acting Insulin Dose (Unadjusted for Body Weight)
Intermediate-/long-acting insulin included Insulin NPH, Ultralente, and Insulin Glargine for both groups.
Time frame: Weeks 1, 2, 3, 4, 6, 9, 12, 18, 26, 39, 52
Mean Total Daily Short-Acting Insulin Dose (Unadjusted for Body Weight)
Short-acting insulin (mg) for the Inhaled Insulin group was Inhaled Insulin. Short-acting insulin (unit) for the Subcutaneous Insulin group included Insulin Lispro, Insulin Aspart, and Regular Insulin.
Time frame: Weeks 1, 2, 3, 4, 6, 9, 12, 18, 26, 39, 52
Mean Total Daily Intermediate-/Long-Acting Insulin Dose (Adjusted for Body Weight)
Intermediate/long-acting insulin included Insulin NPH, Ultralente, and Insulin Glargine for both groups. Dose was adjusted for body weight (units divided by kg).
Time frame: Weeks 1, 2, 3, 4, 6, 9, 12, 18, 26, 39, 52
Mean Total Daily Short-Acting Insulin Dose (Adjusted for Body Weight)
Short-acting insulin (mg) for the Inhaled Insulin group was Inhaled Insulin. Short-acting insulin (unit) for the Subcutaneous Insulin group included Insulin Lispro, Insulin Aspart, and Regular Insulin. Dose was adjusted for body weight (mg divided by kg or units divided by kg).
Time frame: Weeks 1, 2, 3, 4, 6, 9, 12, 18, 26, 39, 52
Lipids
Lipids collected: Total cholesterol, high-density lipoprotein, low-density lipoptrotein, and triglycerides. Lipids data were collected, but not analyzed.
Time frame: Duration of the study
Hypoglycemic Event Rates
A hypoglycemic event was identified by characteristic symptoms; blood glucose levels at 59 mg/dL (3.2 mmol/L) or less with a glucose check; or any glucose measurement 49 mg/dL (2.7 mmol/L) or less, with or without symptoms. Crude event rate=total events divided by subject-months. Subject-months=elapsed number of months a subject was in the study in each time interval.
Time frame: 0 to1 month to > 11 months
Severe Hypoglcyemic Event Rates
An event was severe if the subject was unable to treat him/herself; had at least 1 neurological symptom; or blood glucose of \< = 49 mg/dL or the blood glucose was not measured, but the clinical manifestations were reversed by oral carbohydrates, subcutaneous glucagon, or intravenous glucose. Crude event rate=total events/100 subject-months. Subject-months=elapsed number of months a subject was in the study in each time interval.
Time frame: 0 to 1 month to > 11 months
| Milestone | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Started | 59 | 46 |
| Completed | 46 | 30 |
| Not completed | 13 | 16 |
| Withdrew: Death | 0 | 3 |
| Withdrew: Adverse event | 6 | 3 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Withdrawal by subject | 3 | 5 |
| Withdrew: Other | 3 | 3 |
FEV1 was measured in liters (L) 30 minutes following the administration of ipratropium. Change from baseline: mean of (value of observed FEV1 (L) at treatment duration minus baseline value).
| L | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Week 1 (n=52, 39) | -0.021 ± 0.132 | -0.018 ± 0.125 |
| Week 2 (n=51, 40) | -0.039 ± 0.116 | -0.042 ± 0.120 |
| Week 3 (n=47, 40) | -0.026 ± 0.121 | -0.048 ± 0.145 |
| Week 4 (n=50, 38) | -0.050 ± 0.140 | -0.039 ± 0.151 |
| Week 6 (n=53, 38) | -0.045 ± 0.152 | -0.070 ± 0.165 |
| Week 12 (n=48, 41) | -0.056 ± 0.180 | -0.007 ± 0.187 |
| Week 18 (n=52, 37) | -0.049 ± 0.158 | -0.071 ± 0.195 |
| Week 26 (n=52, 38) | -0.067 ± 0.174 | -0.096 ± 0.189 |
| Week 39, (n=47, 34) | -0.053 ± 0.174 | -0.092 ± 0.232 |
| Week 52 (n=45, 30) | -0.068 ± 0.208 | -0.128 ± 0.184 |
Full PFTs included spirometry pre- and 30-minutes post-ipratropium and were completed between the hours of 6 AM and 10 AM with subjects in the fasting state. Full PFT data were collected, but not analyzed.
No measurements were reported for this outcome.
Full PFTs included DLco pre- and 30-minutes post-ipratropium and were completed between the hours of 6 AM and 10 AM with subjects in the fasting state. Full PFT data were collected, but not analyzed.
No measurements were reported for this outcome.
DLco measured in milliters/minutes/millimeters of mercury (mL/min/mmHg) 30 minutes following the administration of ipratropium. Change from baseline: mean of (value of observed DLco (mL/min/mmHg) at treatment duration minus baseline value).
| mL/min/mmHg | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Week 1 (n=51, 40) | -0.263 ± 1.610 | -0.319 ± 0.984 |
| Week 2 (n=51, 40) | -0.491 ± 1.288 | -0.031 ± 1.106 |
| Week 3 (n=47, 40) | -0.494 ± 1.175 | 0.169 ± 1.303 |
| Week 4 (n=50, 39) | -0.640 ± 1.345 | -0.482 ± 1.321 |
| Week 6 (n=52, 38) | -0.625 ± 1.356 | -0.576 ± 1.226 |
| Week 12 (n=47, 40) | -0.379 ± 1.516 | -0.534 ± 1.506 |
| Week 18 (n=51, 36) | -0.287 ± 1.463 | -0.286 ± 1.796 |
| Week 26 (n=52, 38) | -0.287 ± 1.841 | -0.947 ± 1.643 |
| Week 39 (n=47, 33) | -0.611 ± 1.475 | -0.891 ± 2.137 |
| Week 52 (n=45, 29) | -0.614 ± 1.754 | -0.882 ± 1.720 |
Other PFTs (besides FEV1 and DLco) were measured 30 minutes following the administration of ipratropium. Other PFTs included forced vital capacity (FVC), peak expiratory flow rate (maximal forced expiratory flow) (PEFR\[FEFmax\]), and forced expiratory flow from 25% to 75% of vital capacity (FEF25%-75%). Other PFT data were collected, but not analyzed.
No measurements were reported for this outcome.
Responsiveness was the percent change from the FEV1 value before bronchodilator use to the FEV1 value 30 minutes after bronchodilator use, operationally defined as \[(post-bronchodilator FEV1 minus pre-bronchodilator FEV1 divided by pre-bronchodilator FEV1\] multiplied by 100.
| percent change | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Week 1 (n=52, 39) | 4.890 ± 5.727 | 5.693 ± 7.249 |
| Week 2 (n=51, 40) | 6.132 ± 6.200 | 5.245 ± 6.254 |
| Week 3 (n=47, 40) | 6.346 ± 7.469 | 5.820 ± 8.347 |
| Week 4 (n=50, 38) | 5.177 ± 7.211 | 6.382 ± 9.685 |
| Week 6 (n=53, 38) | 5.988 ± 6.034 | 7.736 ± 10.139 |
| Week 12 (n=48, 41) | 6.473 ± 8.994 | 5.542 ± 6.791 |
| Week 18 (n=52, 37) | 6.700 ± 6.020 | 5.152 ± 8.155 |
| Week 26 (n=52, 38) | 5.585 ± 5.592 | 5.856 ± 8.562 |
| Week 39 (n=47, 34) | 6.634 ± 5.829 | 6.098 ± 9.311 |
| Week 52 (n=45, 30) | 6.030 ± 4.700 | 5.445 ± 8.390 |
FEV1 dose responsiveness 10 and 60 minutes after insulin. FEV1 dose-responsiveness to insulin (defined as the difference between the FEV1 value following a dose of insulin and FEV1 value before a dose of insulin, operationally defined as the post-dose FEV1 value minus pre-dose FEV1 value).
| L | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Baseline, 10 minutes (n=50, 39) | 0.009 ± 0.076 | 0.022 ± 0.106 |
| Baseline, 60 minutes (n=50, 39) | -0.004 ± 0.096 | 0.020 ± 0.127 |
| Week 9, 10 minutes (n=42, 31) | -0.004 ± 0.110 | 0.016 ± 0.096 |
| Week 9, 60 minutes (n=42, 30) | 0.011 ± 0.109 | 0.030 ± 0.116 |
| Week 51, 10 minutes (n=46, 31) | -0.021 ± 0.121 | -0.002 ± 0.084 |
| Week 51, 60 minutes (n=45, 31) | 0.005 ± 0.115 | -0.020 ± 0.141 |
DLco dose responsivness 10 and 60 minutes after insulin. DLco dose-responsiveness to insulin (defined as the difference between the DLco value following a dose of insulin and DLco value before a dose of insulin, operationally defined as the post-dose DLco value minus pre-dose DLco value).
| mL/min/mmHg | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Baseline, 10 minutes (n=48, 39) | -0.461 ± 1.157 | -0.195 ± 0.707 |
| Baseline, 60 minutes (n=49, 39) | -0.597 ± 1.102 | -0.160 ± 1.217 |
| Week 9, 10 minutes (n=41, 30) | -0.182 ± 1.015 | -0.238 ± 1.505 |
| Week 9, 60 minutes (n=42, 29) | 0.013 ± 2.288 | -0.373 ± 1.574 |
| Week 51, 10 minutes (n=44, 31) | -0.465 ± 0.781 | 0.054 ± 1.204 |
| Week 51, 60 minutes (n=44, 31) | -0.395 ± 0.885 | -0.163 ± 1.211 |
Methacholine challenge testing was conducted at selected sites at visits which did not occur at other sites (Weeks -2.9, -0.9, 11, 50 and 52+5). Methacholine challenge was not analyzed as there was only 1 test performed, which was a baseline test, and no methacholine tests performed in subjects using inhaled insulin.
No measurements were reported for this outcome.
All subjects used diary cards to record their daily use of short-acting bronchodilators. Subjects recorded the sum of their short-acting bronchodilator use (puffs of albuterol plus ipratropium plus Combivent®, as applicable) daily, immediately upon arising, and again in the evening or before bed. Mean weekly number of puffs of short-acting bronchodilator used data were collected, but not analyzed.
No measurements were reported for this outcome.
Non-severe COPD exacerbation = additional therapy (systemic corticosteroids, antibiotics, oxygen) needed for worsening respiratory symptoms and/or lung function, not needing hospitalization \> 24 hours. Crude event rate = total events divided by subject-months. Subject-months=elapsed number of months a subject was in the study in each time interval.
| events/subject-month (crude event rate) | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| 0 to 1 week (n=59, 43) | 0.00 | 0.00 |
| > 1 to 2 weeks (n=59, 43) | 0.07 | 0.00 |
| > 2 to 3 weeks (n=59, 43) | 0.00 | 0.00 |
| > 3 to 4 weeks (n=59, 42) | 0.07 | 0.10 |
| > 4 to 6 weeks (n=57, 42) | 0.08 | 0.05 |
| > 6 to 9 weeks (n=56, 42) | 0.05 | 0.03 |
| > 9 to 12 weeks (n=55, 41) | 0.05 | 0.07 |
| > 3 to 6 months (n=52, 41) | 0.02 | 0.01 |
| > 6 to 9 months (n=52, 37) | 0.01 | 0.01 |
| > 9 months (n=50, 35) | 0.01 | 0.02 |
| Overall (n=59, 43) | 0.02 | 0.02 |
Severe COPD exacerbation = a COPD-related hospitalization \> 24 hours. Crude event rate = total events divided by subject-months. Subject-months=elapsed number of months a subject was in the study in each time interval.
| events/subject-month (crude event rate) | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| 0 to 1 week (n=59, 43) | 0.00 | 0.00 |
| > 1 to 2 weeks (n=59, 43) | 0.00 | 0.00 |
| > 2 to 3 weeks (n=59, 43) | 0.00 | 0.00 |
| > 3 to 4 weeks (n=59, 42) | 0.00 | 0.00 |
| > 4 to 6 weeks (n=57, 42) | 0.00 | 0.00 |
| > 6 to 9 weeks (n=56, 42) | 0.00 | 0.00 |
| > 9 to 12 weeks (n=55, 41) | 0.00 | 0.00 |
| > 3 to 6 months (n=52, 41) | 0.00 | 0.00 |
| > 6 to 9 months (n=52, 37) | 0.01 | 0.00 |
| > 9 months (n=50, 35) | 0.00 | 0.00 |
| Overall (n= 59, 43) | 0.00 | 0.00 |
The BDI and TDI measured or quantitated the severity of breathlessness (shortness of breath) in symptomatic subjects. BDI and TDI data were collected, but not analyzed.
No measurements were reported for this outcome.
Change from baseline: mean of (value of observed HbA1c at treatment duration minus baseline value).
| percent | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Week 6 (n=56, 40) | -0.40 ± 0.81 | -0.48 ± 0.60 |
| Week 12 (n=50, 41) | -0.53 ± 0.98 | -0.42 ± 0.65 |
| Week 26 (n=52, 38) | -0.39 ± 0.96 | -0.32 ± 0.79 |
| Week 39 (n=48, 35) | -0.34 ± 1.11 | -0.20 ± 1.01 |
| Week 52 (n=46, 32) | -0.30 ± 1.10 | -0.23 ± 0.84 |
| Week 52 LOCF (n=57, 43) | -0.28 ± 1.03 | -0.26 ± 0.79 |
Change from baseline: mean of (value of observed fasting plasma glucose in milligrams/deciliters (mg/dL) at treatment duration minus baseline value).
| mg/dL | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Week 6 (n=52, 39) | -24.67 ± 69.69 | 2.89 ± 41.17 |
| Week 12 (n=48, 39) | -30.73 ± 52.99 | -0.18 ± 46.25 |
| Week 26 (n=47, 38) | -34.92 ± 61.63 | 10.45 ± 62.80 |
| Week 39 (n=47, 33) | -20.45 ± 56.62 | 10.43 ± 98.53 |
| Week 52 (n=45, 31) | -23.40 ± 65.77 | 12.37 ± 58.01 |
| Week 52 (LOCF) (n=57, 43) | -28.55 ± 65.85 | 2.36 ± 66.51 |
Change from baseline: mean of (value of observed body weight in kilograms (kg) at treatment duration minus baseline value).
| kg | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Week 1 (n=52, 40) | 0.25 ± 1.62 | 0.02 ± 0.98 |
| Week 2 (n=51, 40) | 0.26 ± 1.77 | 0.15 ± 1.73 |
| Week 3 (n=49, 41) | 0.19 ± 2.03 | 0.13 ± 1.90 |
| Week 4 (n=53, 41) | 0.19 ± 1.98 | 0.24 ± 2.13 |
| Week 6 (n=54, 39) | 0.42 ± 2.26 | 0.26 ± 1.94 |
| Week 9 (n=47, 34) | 0.31 ± 2.93 | 0.25 ± 2.31 |
| Week 11 (n=8, 8) | 0.03 ± 2.25 | -0.14 ± 2.97 |
| Week 12 (n=49, 41) | 0.42 ± 3.29 | 0.34 ± 3.69 |
| Week 18 (n=52, 37) | 0.40 ± 3.66 | 0.90 ± 4.01 |
| Week 26 (n=52, 38) | 0.85 ± 3.95 | 1.99 ± 4.03 |
| Week 39 (n=47, 34) | 0.61 ± 4.37 | 2.43 ± 5.21 |
| Week 50 (n=8, 6) | 1.75 ± 4.90 | 6.33 ± 9.06 |
| Week 51 (n=23, 17) | 1.21 ± 4.82 | 2.67 ± 3.28 |
| Week 52 (n=43, 27) | 0.97 ± 5.65 | 3.32 ± 4.68 |
| Week 52 LOCF (n=59, 43) | 0.99 ± 4.20 | 2.40 ± 4.79 |
Intermediate-/long-acting insulin included Insulin NPH, Ultralente, and Insulin Glargine for both groups.
| Units | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Week 1 (n=53, 40) | 43.78 ± 22.20 | 48.18 ± 23.44 |
| Week 2 (n=50, 41) | 44.96 ± 22.50 | 48.04 ± 24.33 |
| Week 3 (n=51, 39) | 47.04 ± 24.36 | 50.53 ± 24.44 |
| Week 4 (n=52, 41) | 47.50 ± 25.94 | 50.30 ± 25.61 |
| Week 6 (n=54, 40) | 49.56 ± 26.61 | 51.34 ± 25.91 |
| Week 9 (n=47, 35) | 48.68 ± 28.61 | 56.72 ± 25.89 |
| Week 12 (n=51, 41) | 49.23 ± 28.46 | 52.32 ± 29.49 |
| Week 18 (n=51, 40) | 50.87 ± 29.32 | 53.83 ± 29.34 |
| Week 26 (n=51, 38) | 50.47 ± 28.83 | 55.78 ± 28.11 |
| Week 39 (n=49, 35) | 49.99 ± 29.00 | 53.10 ± 26.11 |
| Week 52 (n=48, 34) | 50.66 ± 30.63 | 53.39 ± 26.32 |
Short-acting insulin (mg) for the Inhaled Insulin group was Inhaled Insulin. Short-acting insulin (unit) for the Subcutaneous Insulin group included Insulin Lispro, Insulin Aspart, and Regular Insulin.
| mg, Units | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Week 1 (n=54, 40) | 12.34 ± 5.26 | 32.74 ± 21.59 |
| Week 2 (n=51, 41) | 13.03 ± 6.63 | 32.08 ± 22.25 |
| Week 3 (n=52, 39) | 14.10 ± 6.89 | 32.88 ± 21.60 |
| Week 4 (n=53, 41) | 14.17 ± 7.28 | 31.85 ± 22.29 |
| Week 6 (n=55, 40) | 15.17 ± 7.20 | 33.42 ± 22.72 |
| Week 9 (n=48, 35) | 15.82 ± 7.41 | 36.65 ± 22.94 |
| Week 12 (n=52, 41) | 15.64 ± 7.80 | 33.58 ± 23.94 |
| Week 18 (n=52, 40) | 16.47 ± 7.48 | 35.36 ± 26.06 |
| Week 26 (n=52, 38) | 16.71 ± 8.05 | 37.73 ± 26.14 |
| Week 39 (n=49, 35) | 17.22 ± 8.60 | 37.47 ± 26.20 |
| Week 52 (n=48, 34) | 16.85 ± 9.52 | 39.28 ± 25.13 |
Intermediate/long-acting insulin included Insulin NPH, Ultralente, and Insulin Glargine for both groups. Dose was adjusted for body weight (units divided by kg).
| Units/kg | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Week 1 (n=51, 40) | 0.46 ± 0.22 | 0.48 ± 0.19 |
| Week 2 (n=50, 40) | 0.47 ± 0.22 | 0.48 ± 0.20 |
| Week 3 (n=49, 39) | 0.50 ± 0.25 | 0.50 ± 0.21 |
| Week 4 (n=50, 41) | 0.49 ± 0.26 | 0.50 ± 0.21 |
| Week 6 (n=53, 39) | 0.52 ± 0.27 | 0.51 ± 0.21 |
| Week 9 (n=46, 34) | 0.50 ± 0.29 | 0.57 ± 0.21 |
| Week 12 (n=49, 41) | 0.51 ± 0.28 | 0.52 ± 0.24 |
| Week 18 (n=51, 37) | 0.53 ± 0.29 | 0.55 ± 0.24 |
| Week 26 (n=51, 38) | 0.52 ± 0.28 | 0.55 ± 0.22 |
| Week 39 (n=47, 34) | 0.51 ± 0.27 | 0.54 ± 0.24 |
| Week 52, (n=43, 27) | 0.52 ± 0.29 | 0.56 ± 0.21 |
Short-acting insulin (mg) for the Inhaled Insulin group was Inhaled Insulin. Short-acting insulin (unit) for the Subcutaneous Insulin group included Insulin Lispro, Insulin Aspart, and Regular Insulin. Dose was adjusted for body weight (mg divided by kg or units divided by kg).
| mg/kg, Units/kg | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Week 1 (n=52, 40) | 0.13 ± 0.05 | 0.33 ± 0.21 |
| Week 2 (n=51, 40) | 0.14 ± 0.06 | 0.33 ± 0.21 |
| Week 3 (n=49, 39) | 0.15 ± 0.07 | 0.33 ± 0.22 |
| Week 4 (n=51, 41) | 0.15 ± 0.07 | 0.32 ± 0.22 |
| Week 6 (n=54, 39) | 0.16 ± 0.07 | 0.34 ± 0.22 |
| Week 9 (n=47, 34) | 0.17 ± 0.07 | 0.36 ± 0.22 |
| Week 12 (n=49, 41) | 0.17 ± 0.08 | 0.34 ± 0.23 |
| Week 18 (n=52, 37) | 0.17 ± 0.08 | 0.37 ± 0.24 |
| Week 26 (n=52, 38) | 0.18 ± 0.08 | 0.38 ± 0.24 |
| Week 39 (n=47, 34) | 0.18 ± 0.08 | 0.38 ± 0.25 |
| Week 52 (n=43, 27) | 0.18 ± 0.09 | 0.40 ± 0.25 |
Lipids collected: Total cholesterol, high-density lipoprotein, low-density lipoptrotein, and triglycerides. Lipids data were collected, but not analyzed.
No measurements were reported for this outcome.
A hypoglycemic event was identified by characteristic symptoms; blood glucose levels at 59 mg/dL (3.2 mmol/L) or less with a glucose check; or any glucose measurement 49 mg/dL (2.7 mmol/L) or less, with or without symptoms. Crude event rate=total events divided by subject-months. Subject-months=elapsed number of months a subject was in the study in each time interval.
| events / subject-month | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| 0 to 1 month (n=57, 43) | 1.76 | 1.36 |
| > 1 to 2 months (n=56, 42) | 1.25 | 0.98 |
| > 2 to 3 months (n=55, 42) | 1.21 | 0.97 |
| > 3 to 4 months (n=52, 41) | 0.87 | 0.67 |
| > 4 to 5 months (n=52, 40) | 0.96 | 1.01 |
| > 5 to 6 months (n=52, 38) | 0.69 | 1.13 |
| > 6 to 7 months (n=52, 37) | 0.62 | 0.92 |
| > 7 to 8 months (n=51, 36) | 0.67 | 0.75 |
| > 8 to 9 months (n=51, 36) | 0.59 | 0.78 |
| > 9 to 10 months (n=51, 36) | 0.50 | 0.52 |
| > 10 to 11 months (n=49, 34) | 0.75 | 0.51 |
| > 11 months (n=47, 33) | 0.62 | 0.26 |
| Overall (n=57, 43) | 0.89 | 0.84 |
An event was severe if the subject was unable to treat him/herself; had at least 1 neurological symptom; or blood glucose of \< = 49 mg/dL or the blood glucose was not measured, but the clinical manifestations were reversed by oral carbohydrates, subcutaneous glucagon, or intravenous glucose. Crude event rate=total events/100 subject-months. Subject-months=elapsed number of months a subject was in the study in each time interval.
| events / 100 subject-months | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| 0 to 1 month (n=57, 43) | 1.71 | 2.35 |
| > 1 to 2 months (n=56, 42) | 1.79 | 0.00 |
| > 2 to 3 months (n=55, 42) | 0.00 | 0.00 |
| > 3 to 4 months (n=52, 41) | 0.00 | 0.00 |
| > 4 to 5 months (n=52, 40) | 0.00 | 0.00 |
| > 5 to 6 months (n=52, 38) | 0.00 | 0.00 |
| > 6 to 7 months (n=52, 37) | 0.00 | 0.00 |
| > 7 to 8 months (n=51, 36) | 0.00 | 0.00 |
| > 8 to 9 months (n=51, 36) | 1.96 | 0.00 |
| > 9 to 10 months (n=51, 36) | 2.01 | 0.00 |
| > 10 to 11 months (n=49, 34) | 0.00 | 0.00 |
| > 11 months (n=47, 33) | 0.00 | 0.00 |
| Overall (n=57, 43) | 0.64 | 0.22 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Inhaled Insulin | — | — | — |
| Subcutaneous Insulin | — | — | — |
| Event | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Myocardial infarctionCardiac disorders | 1/59 | 3/46 |
| PneumoniaInfections and infestations | 3/59 | 0/46 |
| Coronary artery diseaseCardiac disorders | 0/59 | 2/46 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 2/59 | 0/46 |
| Inguinal herniaGastrointestinal disorders | 0/59 | 1/46 |
| Intestinal obstructionGastrointestinal disorders | 0/59 | 1/46 |
| NauseaGastrointestinal disorders | 0/59 | 1/46 |
| Vomiting projectileGastrointestinal disorders | 0/59 | 1/46 |
| HypothermiaGeneral disorders | 0/59 | 1/46 |
| Ill-defined disorderGeneral disorders | 0/59 | 1/46 |
| Event | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 40/59 | 30/46 |
| Upper respiratory tract infectionInfections and infestations | 12/59 | 6/46 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 7/59 | 9/46 |
| NasopharyngitisInfections and infestations | 10/59 | 6/46 |
| HeadacheNervous system disorders | 10/59 | 3/46 |
| AstheniaGeneral disorders | 9/59 | 5/46 |
| DizzinessNervous system disorders | 8/59 | 7/46 |
| BronchitisInfections and infestations | 8/59 | 2/46 |
| Oedema peripheralGeneral disorders | 5/59 | 6/46 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/59 | 2/46 |
| Age, Customized(participants) | Inhaled Insulin | Subcutaneous Insulin | Total |
|---|---|---|---|
| 36 to 45 years | 1 | 3 | 4 |
| 46 to 55 years | 10 | 4 | 14 |
| 56 to 65 years | 20 | 23 | 43 |
| 66 to 75 years | 27 | 15 | 42 |
| > 75 years | 1 | 1 | 2 |
| Sex: Female, Male(Participants) | Inhaled Insulin | Subcutaneous Insulin | Total |
|---|---|---|---|
| Female | 17 | 9 | 26 |
| Male | 42 | 37 | 79 |
| Primary Diagnosis (Diabetes Type I or II)(participants) | Inhaled Insulin | Subcutaneous Insulin | Total |
|---|---|---|---|
| Type I | 7 | 6 | 13 |
| Type II | 52 | 40 | 92 |
The record gives a start of Jan 2003, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2009, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin